I wholeheartedly concur! The current trajectory appears exceedingly promising over the three-month period you referenced. I eagerly anticipate the outcomes of the Phase 2 trials in Pitt Hopkins syndrome and Angelman syndrome, given the significant potential attributed to NNZ-2591, which surpasses that of Rett Syndrome by more than fivefold. I perceive a confluence of favorable factors. Furthermore, the noteworthy achievement of a $157 million profit after tax for 2023 adds to the company's compelling narrative.
- Forums
- ASX - By Stock
- NEU
- Medium term milestones
Medium term milestones, page-90
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$19.45 |
Change
-0.820(4.05%) |
Mkt cap ! $2.473B |
Open | High | Low | Value | Volume |
$20.40 | $20.50 | $18.92 | $7.926M | 405.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 188 | $19.44 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$19.46 | 148 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 795 | 19.450 |
5 | 279 | 19.430 |
3 | 703 | 19.420 |
2 | 204 | 19.410 |
4 | 955 | 19.400 |
Price($) | Vol. | No. |
---|---|---|
19.470 | 179 | 5 |
19.480 | 136 | 3 |
19.490 | 503 | 8 |
19.500 | 241 | 4 |
19.510 | 392 | 5 |
Last trade - 12.16pm 04/06/2024 (20 minute delay) ? |
|
|||||
Last
$19.34 |
  |
Change
-0.820 ( 5.01 %) |
|||
Open | High | Low | Volume | ||
$20.39 | $20.46 | $18.92 | 155160 | ||
Last updated 12.34pm 04/06/2024 ? |
Featured News
NEU (ASX) Chart |